Vanda Pharmaceuticals ((VNDA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vanda Pharmaceuticals is conducting a study titled ‘Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies.’ The study aims to assess the safety and tolerability of Trichostatin A in patients with challenging blood cancers, highlighting its potential significance in advancing treatment options for these conditions.
The intervention being tested is Trichostatin A, an experimental drug administered via intravenous infusion, designed to improve outcomes for patients with relapsed or refractory hematologic malignancies.
This interventional study follows a single-group assignment model with no masking, focusing on treatment as its primary purpose. Such a design allows for direct observation of the drug’s effects on participants.
The study began on September 27, 2018, and is currently recruiting participants. The last update was submitted on July 14, 2025, indicating ongoing progress and adjustments as needed.
The outcome of this study could influence Vanda Pharmaceuticals’ stock performance, as successful results may enhance investor confidence and market position. It is crucial for investors to monitor this study’s progress, considering the competitive landscape of hematologic treatments.
The study is ongoing, with further details accessible on the ClinicalTrials portal.